World Ovarian Cancer Day | 2019

Keytruda wins FDA nod for treating Kidney Cancer Merck’s Keytruda has recently got the U.S. FDA approval to be administered for Kidney Cancer. The drug Keytruda was approved in combination with Pfizer’s Inlyta for the treatment of advanced renal carcinoma. This therapy could prove to be serious for competition B...

Each country has a unique system, politics, and economy. Different policies are designed to suit people of different countries. Same goes with the Healthcare industry. Healthcare is financed either through government voluntary or compulsory insurances or via private corporations and NGOs. Industrialised and more d...

Amgen reveals the price of EVENITY Amgen has set the price of its newly launched Osteoporosis drug Romosozumab (Evenity). Worth USD 21,900 per annum or USD 1,825 a month, the bone-building drug was approved by the FDA recently for the treatment of Osteoporosis in postmenopausal women and now will be available i...

FDA gives thumbs-up to Balversa The U.S. FDA has granted approval of Balversa (erdafitinib) to Belgium-based Janssen Pharmaceutica, for the treatment of advanced or metastatic bladder cancer. This drug is the first ever approved target-specific medication targeting susceptible FGFR genetic mutations, and for can...

Gene Therapy is a way to introduce a normal working gene in the place of a mutated one which might result in some kinds of abnormalities. Gene Therapy is a novel way to express novel proteins, and re-design the genome to prevent any disease. The concept here is some disorders are caused due to their defect in a sin...

Inozyme Pharma Raises USD 67 Million in Series A2 Financing Inozyme Pharma- a Boston-based biotechnology company, solely focused on developing novel therapies to treat rare diseases, has raised USD 67 million. The company plans to use this funding to progress its lead asset INZ-701, into clinical trials. INZ-701...